Closed-Loop Impact on Chronic Kidney Disease in Type 2 Diabetes

Recruiting N/A Interventional Study
Type 2 Diabetes Chronic Kidney Disease Stage 3
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
76 (estimated)
Sponsor
Heba Al-Alwan · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The main objective of this study is to evaluate the effect of fully automated closed-loop glucose control on renal tissue oxygenation among people with type 2 diabetes and chronic kidney disease. This is a single-center, open-label parallel design study that will compare 26 weeks of fully-automated closed-loop glucose control with standard insulin therapy and continuous glucose monitoring, follow…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Informed consent signed by the subject * Age 18 years and older * Type 2 diabetes diagnosed for at least 12 months * Treatment with insulin therapy for at least 6 months * CKD defined either as an eGFR 30-59 ml/min/1.73m² or presence of albuminuria \> 3 mg/mmol (stage A2 or A3…
Contacts

Heba Al-Alwan, MD, PhD

+4179 556 27 98

heba.al-alwan@chuv.ch

CONTACT